Dr. Yanai Ben Gal, Director of the Cardiothoracic Surgery Department at Ichilov: “The valve offers relief for high risk patients for whom no surgical solution was available, resulting in multiple hospitalizations and even a shorter life expectancy”.
Tiara – an innovative valve for the treatment of mitral valve insufficiency (regurgitation), was implanted recently for the first time in Israel in a procedure of minimal invasive surgery performed at the Ichilov Medical Center by a multidisciplinary team led by Dr. Yanai Ben Gal, Director of the Cardiothoracic Surgery Department and with the collaboration of the
Cardiology Department and the Anesthesiology Division.
Mitral valve regurgitation is the most common valvular impairment and it is caused by a defect in the valve or by heart muscle impairment. To date, only percutaneous mitral valve replacements have been performed in Israel, and this is the first time that a designated valve is implanted in replacement of the mitral valve by means of a minimal invasive surgery as explained above.
The Tiara valve is an innovative valve currently under investigation and for the time being it is implanted worldwide in the framework of preliminary trials in human beings. One of the developers of the groundbreaking valve is an Israeli physician from
Ichilov Hospital: Prof. Shmuel Banai, Director of the Interventional Cardiology Unit.
To date, 31 Tiara valves have been implanted successfully at the most advanced medical centers in the world in the following countries: Canada, USA, Belgium, Italy, Germany and Switzerland. This valve has been implanted in patients who are at too great a risk to undergo the regular surgery which involves the opening of the chest and stopping the heart using a heart-lung machine. Until now, these patients had no adequate therapeutic solution, which resulted in multiple hospitalizations and even a shorter life expectancy.
Dr. Ben Gal says: “The valve replacement took place in a hybrid operating theater under imaging (as in the catheterization lab) and guided by an intraesophageal 3-D Echo, performed by a multidisciplinary team which included interventional cardiologist and Echo personnel. The valve was designed in such a way that allows it to function from the very early stages of its deployment, and it transports blood from the left atrium to the left ventricle and to the rest of the body’s organs”.
The first patient to undergo the replacement is a 71-year-old Israeli male who suffered from
severe heart failure and had undergone several hear surgeries in the past. He suffered from multiple risk factors and consequently there was no surgical solution for him up until now. The implantation, as aforesaid, was successful and at the end of the procedure the artificial valve functioned well with no regurgitation. The patient was weaned off mechanical ventilation a short while thereafter and was moved for further observation in the department, and he is now completely stable and is expected to be discharged in the upcoming days. “This procedure is a hallmark of our ability to treat the impaired mitral valve problem and we hope that in the future, a growing number of patients will be able to enjoy the replacement through this approach”, sums Dr. Ben Gal.